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cBarbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CAa b s t r a c tCardiovascular disease (CVD) remains the leading cause of death for women in the United States. The role of primary prevention of
CVD is a necessary focus of healthcare, given the overall prevalence of CVD and its risk factors in women. In 2013, the American
College of Cardiology and the American Heart Association released new guidelines on the treatment of blood cholesterol to
reduce atherosclerotic cardiovascular risk (ASCVD) in adults that were based on results of randomized controlled trials. These
guidelines apply to both men and women. Achievement of a target cholesterol level is no longer part of the guidelines. Rather, the
guidelines recommend an appropriate and ﬁxed intensity of a statin based on calculation of an individual's risk of ASCVD or in
diabetics or those with severely elevated LDL-C for primary prevention. The new guidelines emphasize statin therapy over other
lipid-lowering therapy. The new guidelines are evidence-based, coming from randomized control trials that have clearly
demonstrated improved outcomes using statin therapy in those with ASCVD and those at high risk of ASCVD, not based on LDL
targets but rather LDL lowering. This evidence-based approach to ASCVD prevention should be used in women. There were no
speciﬁc sex differences in the new guidelines, and the focus of this article is to provide the evidence to support the use of these
guidelines in women.
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death for women in the United States, with an estimated
400,332 women dying of cardiovascular disease in 2010 [1].
Although there have been noted reductions in mortality from
CVD in women owing to better treatment of CVD, this has
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Table 1 – Women in primary prevention randomized control trials of statins.
Study Number of women enrolled Total enrolled studied Percent women (%) Mean age (years) Drug name
ACAPS 445 919 48 61 Lovastatin
AFCAPS/
TexCAPS
997 6605 15 62 Lovastatin
HPS 1816 5963 30 NA Simvastatin
ALLHAT 5051 10,355 49 NA Pravastatin
ASCOT 1942 10,305 30 NA Atorvastatin
MEGA 5356 7832 69 60 Pravastatin
PROSPER 1894 3239 58 75 Pravastatin
JUPITER 6801 17,802 38 68 Rosuvastatin
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focus of primary prevention of CVD is necessary to not only
reduce mortality from CVD but also to reduce the overall
impact of CVD on the overall health of the nation and its
economic burden on the USA healthcare system.
Identifying and treating CVD risk factors has become a
focus of the American Heart Association in order to reduce
the burden of CVD in the United States [3]. There is signiﬁcant
evidence showing that controlling CVD risk factors is far from
optimal. Based on the NHANES III study, o7.5% of the
population met six of the seven key CVD health metrics
(including not smoking, eating a healthy diet, being physi-
cally active, and having a normal weight, blood pressure,
glucose level, and cholesterol level) [4]. In addition, a large
analysis of 18 studies from the United States showed that in
257,384 participants, only 3% of persons had their key CVD
risk factors optimally managed [5]. By focusing on identiﬁca-
tion and treatment of CVD risk factors, the impact on CVD
will be greater because of the ability to prevent (rather than
treat) CVD.
In 2013, a joint task force from the American College of
Cardiology (ACC) and the American Heart Association (AHA)
released new guidelines on the treatment of blood choles-
terol to reduce atherosclerotic cardiovascular risk (ASCVD)
in adults [6]. The biggest change in these guidelines that
applies to both men and women is the removal of a target
cholesterol level. Instead, the guidelines recommend ﬁxed
intensity of a statin based on whether they are in a statin
beneﬁt group. In primary prevention, these include, high-
risk groups such as those with elevated levels of LDL-C on a
primary basis or those with diabetes, aged 40–75 years, and
LDL-C level 70–189 mg/dl. Those in a lower risk primary
prevention group having a 10-year estimated ASCVD risk
Z7.5 are also shown to beneﬁt, but membership in this
group does not equate with statin treatment. This occurs
only after a clinician–patient risk/beneﬁt discussion thatTable 2 – Women in secondary prevention randomized contro
Study Number of women Total enrolledstudied
4S 827 4444
PLACII 22 151
CARE 576 4159
LIPID 1516 9014
HPS 3266 14,573
PROSPER 1106 2565
SPARCL 1908 4731addresses other risk factors and optimal lifestyle, the poten-
tial for beneﬁt vs the potential for adverse effects, or
drug–drug interactions with statin therapy and includes an
informed patient preference. The new guidelines emphasize
statin therapy over other lipid-lowering treatments and
have eliminated past recommendations to treat to a speciﬁc
low-density lipoprotein (LDL) or non-high-density lipopro-
tein (non-HDL) goal. There were no speciﬁc sex differences
in the guidelines released. Nonetheless, the data on which
these guidelines were made were inﬂuenced by trials that
had relatively fewer women and did not often report sex-
speciﬁc results. More recent trials have included more
women, and these results have impacted the recommenda-
tion of the newest lipid guidelines (Tables 1 and 2).Does the ASCVD risk assessment overestimate
risk in women?
Critics of the new guidelines on cholesterol management
have suggested that the risk score calculator recommended
in the guidelines overestimates risk. Nonetheless, the ASCVD
risk calculator was based on more than one population and
is a pooled cohort equation that was developed and vali-
dated on Caucasian and African American men and women
[7]. The pooled cohorts included participants from several
large NHLBI-sponsored cohort studies that were both geo-
graphically and racially diverse, such as the Atherosclerosis
Risk in Communities (ARIC) Study [8], the Cardiovascular
Health Study [9], the Coronary Artery Risk Development
in Young Adults (CARDIA) Study [10], the Framingham [11],
and the Framingham Offspring Study [12]. Subsequent
reports have validated the accuracy of the ASCVD risk
calculator, including women [13,14]. Nevertheless, given
the populations on which these were developed, these
may overestimate risks in Hispanic-Americans and Eastl trials of statins.
Percent women (%) Mean age (years) Drug name
19 61 Simvastatin
15 62 Pravastatin
14 61 Pravastatin
17 62 Pravastatin
22 NA Simvastatin
43 76 Pravastatin
40 64 Atorvastatin
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Americans, as addressed by the guideline authors. At this
time, there is limited data on these racial groups, so no
speciﬁc adjustment has been made in the current risk score
assessment.
One study that was released almost immediately after the
guidelines were released suggested the new ASCVD risk
calculator overestimated risk by 75–150% [15]. The three
cohorts they used to demonstrate this included the Nurses'
Health Study, The Women's Health Initiative, and the Physi-
cians' Health Study. In all of these studies, it should be noted
that risk factors were self-reported. The ﬁrst study and theFig. 1 – Validation of the atherosclerotic cardiovascular disease
atherosclerotic cardiovascular disease risk among REGARDS par
equations. LDL-C indicates low-density lipoprotein cholesterol.
stroke. (For interpretation of the references to colour in this ﬁgulater study are not representative of the population as a
whole, since they are generally healthier cohorts than the
general population, with access and use of lipid-lowering
therapy. In addition, these studies lacked active surveillance
for all ASCVD events, and as such, their ﬁndings of the
effectiveness of this tool were not accurate.
In contrast, when the ASCVD risk score estimate was
assessed in the Reasons for Geographic and Racial Differ-
ences in Stroke (REGARDS) study, the ASCVD risk calculator
appears to calculate risk relatively accurately [13]. The
REGARDS study is an observational study of 18,498 black
and white persons aged 45–79 years, with 58% being women.pooled cohort risk equations. Observed and predicted
ticipants predicted risk determined using the pooled cohort
REGARDS, reasons for geographic and racial differences in
re, the reader is referred to the web version of this article.)
Fig. 2 – Percent of US adults who would be eligible for statin
therapy for primary prevention, according to set of
guidelines and age group. Shown here are the proportions of
adults in two age groups (40–59 years and 60–75 years)
without cardiovascular disease who would be eligible for
statin therapy for primary prevention of cardiovascular
disease under the ATP-III guidelines and the 2013 ACC–AHA
guidelines, according to the indication for therapy (elevated
LDL cholesterol level, the presence of diabetes, or the
predicted risk of a cardiovascular event according to the set
of guidelines). (Reproduced with permission from Pencina
et al. [16].)
T R E N D S I N C A R D I O V A S C U L A R M E D I C I N E 2 5 ( 2 0 1 5 ) 8 4 – 9 4 87When applying the ASCVD risk calculator to those persons
not on a statin, its ASCVD risk predictions were quite similar
to the observed event rates (Fig. 1). This analysis was limited
to only 5 years of observed event rates since the ongoing
REGARDS cohort did not have 10-year follow-up data at the
point of analysis.
When applying the ASCVD risk assessment tool to the
National Health and Nutrition Examination Surveys of 2005–
2010, they did ﬁnd that potentially more adults in the US
population would be eligible for statin treatment based on the
new guidelines, increasing from 43.2 million (37.5% of the
population) to 56 million (48.6%). This increase was greatest
in adults without cardiovascular disease, particularly more
men than women would be recommended statin treatment
based on the newer guidelines, in addition to obese and older
adults (aged: 60–75 years), and those with higher blood
pressure (Fig. 2) [16]. Based on the NHANES population, the
authors estimated that the likely effect of the full adoption of
the new guidelines would result in the prevention of 475,000
future cardiovascular events.ACC/AHA guidelines vs other guidelines in
women
In a Dutch study of 4854 people with a mean age of 65 years,
of which 54.5% were women, the ACC/AHA guidelines rec-
ommended statin therapy in 66% of women. In contrast, the
older ATP-III guidelines would have recommended treatment
in 36% of women, and the ESC guidelines would recommend
treatment in 39.1% of women. With the new guidelines, the
average predicted risk compared with the observed major
ASCVD events was 21.5% vs 12.7% for men and 11.6% vs 7.9%
for women. Despite its overestimation of risk in both sexes,similar overestimation occurred with the ATP-III and ESC
models [17].
The Dallas Heart Study was used to analyze the implica-
tions of the new ASCVD risk score in place of the ATP-III
recommendations on ASCVD event reduction and efﬁcacy of
statin utilization [18]. This multi-ethnic population that
makes up the Dallas Heart Study is 49.9% women. A relative
increase of 28% of people were eligible for statin therapy
based on the ACC/AHA guidelines compared with the ATP-III
guidelines (22% vs 17%, respectively). The ASCVD event rate
in the newly statin-eligible persons was 15.8%, with an
estimated reduction in one ASCVD event for each additional
14 persons treated with a high-intensity statin and 22
persons treated with a moderate-intensity statin. A 37.1%
net increase in statin-eligibility was seen for those with
ASCVD events, in contrast with a 3.9% net increase in those
without events, with a net reclassiﬁcation improvement of
0.332 (P o 0.0001). It was estimated that by using the ACC/
AHA guidelines over the ATP-III guidelines, an additional
3.6–4.9 ASCVD events per 1000 persons screen could be
prevented [18].Which women need cholesterol treatment?
The ACC/AHA cholesterol guidelines recommends statin
therapy for four speciﬁc beneﬁt groups [6]. These include
the following: Individuals with any form of clinical ASCVD
 Individuals with a primary elevation of LDL cholesterol
levels Z190 mg/dl Individuals with diabetes, aged 40–75 years with LDL
cholesterol levels between 70 and 189 mg/dl and without
any evidence of ASCVD Individuals without evidence of ASCVD or diabetes but
with LDL cholesterol levels between 70 and 189 mg/dl and
a 10-year risk of ASCVD Z7.5%.
In the last category, the ASCVD risk score does not auto-
matically mean statin treatment without any further consid-
eration. The next step should be that the clinician and patient
must ﬁrst engage in a “beneﬁt/risk discussion” that addresses
other risk factors, lifestyle, and includes an informed patient
preference. If lifestyle modiﬁcations are ineffective or not
implemented by the patient, the guidelines recommend
initiating either moderate- or high-intensity statin therapy
depending on the patient's risk, as calculated with the ASCVR
risk calculator. Those with ASCVD should be treated with a
high-intensity statin, in order to achieve a 50% reduction in
the LDL cholesterol level (Fig. 3). In young individuals under
the age of 40 years, additional factors such as a family history
of premature ASCVD and/or a primary elevation of LDL-C
Z160 mg/dl could inform the risk discussion as these might
be candidates for statin therapy. Similarly, in older women
over the age of 60 years, additional factors that could improve
net reclassiﬁcation recommended by the guidelines include
hs-CRP Z2.0; coronary artery calcium (CAC) score Z300 or
Z75th percentile based on age, sex, and ethnic groups; or an
ankle–brachial index o0.9.
Fig. 3 – Summary of statin initiation recommendations for the treatment of blood cholesterol to reduce ASCVD risk in adults.
(Reproduced with permission from Stone et al. [6].)
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When discussing the effectiveness of statins in secondary
prevention, there is signiﬁcant evidence that statins work
equally effectively in women, in the studies that did include
women [19–21]. In a meta-analysis of all lipid-lowering trials
from 1996 to 2003, there were eight trials that included 8272
women with known CVD. Of the eight trials, ﬁve involved statin
therapy as the lipid-lowering agent and involved all but 249
women. This analysis showed that statins in women with CVD
signiﬁcantly reduced coronary heart disease events, heart
disease mortality, nonfatal myocardial infarction, and revascu-
larization even if it did not reducemortality from all-causes [22].What is more controversial is the effectiveness of statins
in primary prevention in women. There has been great
contention in the cardiology community about this, including
a discussion that made its way into a New York Times
editorial [23]. But even prior to the new guideline release,
there had been some studies done suggesting the lack of
effectiveness of statins in primary prevention in both women
and men. Reviewing the literature regarding statins and lipid-
lowering agents, the fact remains that too few women were
included in the majority of trials until recently. Moreover,
even when women were included in trials, studies often did
not provide sex-speciﬁc results and often reported aggregated
events as a primary end point rather than individual out-
comes [24].
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that included women was unable to demonstrate any bene-
ﬁcial effect of lipid-lowering therapy [22]. This analysis
included six randomized control trials (with all but one trial
using a statin) and cumulatively included 11,435 women. The
effect of statin therapy compared with placebo failed to
show any mortality beneﬁt or reduction in cardiac event.
Nonetheless, the true effect of the therapy was not clear
because there were relatively few events that occurred
during follow-up. In addition, the women included were
relatively young and the follow-up period was fairly short
(2.8–6 years).
More recently, a meta-analysis included more recently
completed trials that enrolled relatively more women than
in the past. One such study took all published randomized
controlled trials of statin therapy done before 2010 in inter-
mediate- to high-risk persons without CVD at baseline [25].
The authors chose randomized controlled trials of intermedi-
ate- to high-risk persons, ultimately including 11 studies and
65,229 participants. The analysis was unable to show any
beneﬁt for statin therapy on all-cause mortality in these
higher risk persons over an average treatment period of 3.7
years. Two of the studies included were in diabetics without
clinical manifestation of coronary heart disease. In addition,
there was no sex-speciﬁc analysis performed given that two
of the 11 trials were exclusively male, and even in the studies
that did include women, there were ultimately more men
than women overall. Nonetheless, this analysis did include
the Justiﬁcation for the Use of Statins in Prevention: An
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial as
one of the 11 studies included which has enrolled the most
women to date [6801 women enrolled out of the 17,802
participants (38.2%)], in comparison with any of the prior
primary prevention lipid-lowering trials [26].
Two other meta-analyses were done over the same time
period but examined only those that included women, and
only looked at randomized placebo-control trials of statins
and its effect on primary prevention. The ﬁrst meta-analysis
included 11,404 participants from six trials, with an average
follow-up duration of 4.25 years. Again, a non-signiﬁcant
reduction in all-cause mortality was seen, but there was a
signiﬁcant reduction in coronary heart disease events with a
summary risk ratio of 0.78 (95% CI: 0.64–0.96; P ¼ 0.02) [27].
The second meta-analysis was done by the JUPITER inves-
tigators who performed a meta-analysis of placebo-controlled
statin trials that included predominantly or exclusively pri-
mary prevention populations of women, and was similar to
the meta-analysis above, using the same study populations
but also included the Pravastatin in Elderly Individuals at Risk
of Vascular Disease (PROSPER) trial even though the earlier
investigators did not use this because it included both
primary prevention and secondary prevention [28]. Whether
they examined the exclusively primary prevention trials or all
the trials, the meta-analysis demonstrated a reduction in
CVD events with statin therapy compared with placebo in
women, with the exclusively primary prevention group of
women having a Hazards Ratio of 0.63 (95% CI: 0.49–0.82, P o
0.001) in those randomized to a statin. Similar ﬁndings were
seen in the predominantly primary prevention analysis
(Fig. 4). Both meta-analyses included the Antihypertensiveand Lipid Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT-LLT), which had issues related to adherence, dem-
onstrated by a lower than expected LDL lowering for those
randomized to the statin when compared with other trials. As
such, its negative results (lack of a beneﬁt with statin treat-
ment compared with placebo) will affect both of these
analyses, given the size of this trial [29].
The JUPITER trial does deserve some mention on its own,
given that it is one study that did do a sex-speciﬁc analysis
and enrolled the greatest number of women compared with
any other trial [28]. This trial was a placebo-controlled trial of
primary prevention based on elevation of high-sensitivity
C-reactive protein (hs-CRP) 42.0 mg/L with LDL cholesterol
o130 mg/dl. The primary end point of this study was a
composite end point of myocardial infarction, stroke, hospi-
talization of unstable angina, arterial revascularization, or
CVD death. This study was terminated early because of
beneﬁt seen in the treatment arms, resulting in a median
follow-up of 1.9 years. There was similar risk reduction in
both sexes in those treated with rosuvastatin compared with
placebo, with a Hazard Ratio of 0.54 for women (95% CI: 0.37–
0.80, P ¼ 0.002) and 0.58 for men (95% CI: 0.45–0.73, Po 0.001).
For women, there was speciﬁcally a signiﬁcant reduction in
the rates of revascularization and unstable angina and non-
signiﬁcant reductions in the other components of the primary
end point. There was no signiﬁcant reduction in all-cause
mortality for either sex, but this was a relatively short
duration in a primary prevention population, where mortality
rates would be expected to be low overall.
Nonetheless, even if statins have not been adequately
tested to save lives in primary prevention in women, this
absence of adequate data does not mean statins have not
been shown to be beneﬁcial. They have been shown to reduce
adverse events (hospitalization for unstable angina and
coronary revascularization), which is important. The lack of
adequate data to establish if there is an all-cause mortality
beneﬁt in primary prevention for women does not mean that
statins should not be used in women at high risk for ASCVD.
What it means is that an adequately powered randomized
control trial for a long enough duration needs to be done to
establish such a beneﬁt exists. To date, this has not been
answered. As long as women are under-represented in
clinical trials, we will continue to lack sufﬁcient data to make
treatment decisions on the 51% of the population. Women
are not a special sub-group that is under-represented in the
population, and should stop being labeled as such. All studies
should be adequately powered for sex-speciﬁc analysis in the
future so that it can be properly established if the drugs we
use in women are safe and effective in women. Nonetheless,
given what we know to date, the new cholesterol guidelines
state the women should be treated with statins for both
primary prevention and secondary prevention, where the
beneﬁt outweighs the risk, with an individualized assessment
for all patients.Are statins safe in women?
There are no data to support that statins are less safe
in women when compared with men, and systematic
Fig. 4 – Meta-analysis of women from primary prevention trials. RR of allocation to statin vs placebo in women in relation to
CVD in exclusively primary prevention trials (A), predominantly or exclusively primary prevention trials, (B) and of total
mortality (C and D). The size of the squares is proportional to the number of events. Mean age, percent diabetic, and statin
dose were as follows: AFCAPS/TexCAPS: 63 years, 3%, and lovastatin 20–40 mg/d, respectively; ALLHAT-LLT: 66 years, 35%,
and pravastatin 20–40 mg/d; ASCOT-LLA: 63 years, 24%, and atorvastatin 10 mg/d; MEGA: 60 years, 18%, and pravastatin 10–
20 mg/d; and JUPITER: 69 years, 0%, and rosuvastatin 20 mg/d. (Reproduced with permission from Mora et al. [28].)
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the cardiovascular beneﬁts of statins outweigh non-
cardiovascular harms in patients above a certain threshold
of cardiovascular risk [30].
Myopathies: Myopathies are rumored to occur more fre-
quently in women compared with men, yet the JUPITER trial,
which enrolled the greatest number of women of any statin
trial to date demonstrated no differences in the rates of
myopathies or muscle disorders between men and women,
regardless of treatment assignment 28. The guidelines do not
recommend routine measurement of creatine kinase in
individuals receiving statin therapy, but rather suggest that
it should be reserved for those with muscle symptoms.
Nonetheless, it may be reasonable to measure a baseline
creatine kinase in those with an increased risk for adverse
muscle events, including those with a personal or family
history of statin intolerance or muscle disease, clinical
presentation, or concomitant drug therapy that may increase
the likelihood of myopathy, but these guidelines are not sex-
speciﬁc.Cancer: The exposure time of most of these trials is too
short to associate statin exposure to cancer risk. The JUPITER
trial showed no increase in cancer deaths in women, but this
study was stopped early by the independent Data and Safety
Monitoring Board due to highly signiﬁcant differences in the
intervention and placebo groups [28]. One recent study in
women has related the risk of invasive breast cancer to long-
term statin use [31]. In women with a diagnosis of hyper-
cholesterolemia who used statins for 10 or more years, there
was a signiﬁcant association with any invasive breast carci-
noma, with the odds of breast cancer being at least twice that
of non-users of statins. Nonetheless, this was not a random-
ized control trial but rather a case–control analysis and was
certainly subject to recall bias and selection bias. Since CVD
risk factors in women overlap risk factors for breast cancer, it
is possible that statin use is associated with particular life-
style and CVD risk factors, and this association is due to these
factors rather than statin use. Further, statin-related reduced
CVD may allow subjects to live long enough to develop other
age-related disease. This ﬁnding is in contrast with the
Fig. 5 – Percent of women in statin trials and the odds of development of diabetes. Meta-regression of percent of women on OR
for incident diabetes. Only trials examining statin vs nonstatin placebo or control arms are represented. The error bars
represent the 95% CIs. The adjusted HR for diabetes from the WHI is plotted for comparison (open circle); its data were not
used in the regression calculation. The three trials (JUPITER, PROSPER, and SPARCL) that individually had signiﬁcant rates of
diabetes had higher proportions of women (435%) than usually included in statin trials (o25%), while the one trial
(WOSCOPS) suggesting reduced diabetes consisted only of men. (Reproduced with permission from Goodarzi et al. [44].)
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between statin use and breast cancer over a long period of
time, with a much larger cohort (154,587 postmenopausal
women with 7430 cases of breast cancer over an average of
10.8 years) for observation [32]. The WHI reported an 18% lower
risk of breast cancer incidence amongst users of lipophilic
statins compared with statin non-users (P ¼ 0.02) [33,34]. A
number of other studies have not shown an association with
statin use and breast cancer occurrence [35,36], and some
have demonstrated a reduce risk of breast cancer recurrence
with lipophilic statin (simvastatin) use [37]. The CholesterolTable 3 – Intensity of statin therapy.
High-intensity statin therapy Moderate-intensity s
Daily dose lowers LDL-C on average, by
approximately Z50%
Daily dose lowers LD
approximately 30%
Atorvastatin (40a)–80 mg Atorvastatin 10 (20)m
Rosuvastatin 20 (40)mg Rosuvastatin (5) 10 m
Simvastatin 20–40 m
Pravastatin 40 (80)m
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg bid
Pitavastatin 2–4 mg
Adapted with permission from Stone et al. [6].
Speciﬁc statins and doses are in bold that were evaluated in Randomized
FDA but were not tested in the RCTs reviewed are listed in italics.
Individual responses to statin therapy varied in the RCTs and should be e
a less-than-average response.
a Evidence from one RCT only: down-titration if unable to tolerate atorv
b Although simvastatin 80 mg was evaluated in RCTs, initiation of simvas
to the increased risk of myopathy, including rhabdomyolysis.Treatment Trialists meta-analysis did not show an increase in
any cancer with statins compared with placebo [38].
Hepatic dysfunction: The guidelines recommend baseline
assessment of ALT levels before starting statin therapy given
that this was done prior any of the randomized control trials.
There is no recommendation to monitor ALT levels, unless
there is suspected hepatic dysfunction, since in randomized
controlled trials of statins, there was no signiﬁcant difference
in ALT elevation between the placebo or statin groups.
Diabetes: Statins may modestly increase the risk for
diabetes based on what has been seen in randomizedtatin therapy Low-intensity statin therapy
L-C on average, by
to o50%
Daily dose lowers LDL-C on
average, o30%
g Simvastatin 10 mg
g Pravastatin 10–20 mg
gb Lovastatin 20 mg
g Fluvastatin 20–40 mg
Pitavastatin 1 mg
Control Trials (RCT). Statins and doses that are approved by the US
xpected to vary in clinical practice. There might be a biologic basis for
astatin 80 mg.
tatin 80 mg or titration to 80 mg is not recommended by the FDA due
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high-intensity statin with two or more components of the
metabolic syndrome (Fig. 5). In the JUPITER trial, women
taking rosuvastatin had a small but signiﬁcant increase in
HbA1c compared with placebo (HbA1c 5.9 vs 5.8, P ¼ 0.001), in
addition to a greater risk of developing new diabetes (1.53 vs
1.03 per 100 person-years, respectively; HR ¼ 1.49; 95% CI:
1.11–2.01; P ¼ 0.008) compared with men (1.36 vs 1.20 per 100
person-years, respectively; HR ¼ 1.14; 95% CI: 0.91–1.43; P ¼
0.24) [28]. Within this trial, 80% of incident diabetes occurred
in those with impaired fasting glucose at study entry. The
only statin trial to date to show a reduction in the risk of
diabetes with statin compared with placebo was the West of
Scotland Coronary Prevention Study (WOSCOPS), which used
pravastatin but did not enroll any women in that trial [39]. In
the Women's Health Initiative, reported statin use was asso-
ciated with an increased risk of self-reported new-onset
diabetes in postmenopausal women (HR ¼ 1.48, 95% CI: 1.38–
1.59) but translated into an absolute risk rate of one case of
incident diabetes for every 1000 women taking statins per year
[40]. The guidelines themselves indicate that high-intensity
statins are associated with an incidence of diabetes of 0.3 per
100 persons treated, compared to 0.1 per 100 in those without
statin treatment. It is recommended that screening for new-
onset diabetes been done while on statin therapy but with the
recognition that the ASCVD risk reduction beneﬁt outweighs
the excess potential risk of diabetes. A recent analysis of the
Dallas Heart Study demonstrated that statin-related CVD event
reduction far outweighs the elevated diabetes risk [18].
Statins in pregnancy: Statins are listed as pregnancy category
X, and should not be used in women of childbearing potential
unless these women are using effective contraception and
are not nursing.The new guidelines and the role of risk factor and
lifestyle optimization in women
The discussion above focused on the evidence related to the
effectiveness and risks of statins in women. Some women
will need statin therapy independent of the ASCVD risk score.
Nonetheless, all women will beneﬁt from lifestyle and risk
factor modiﬁcation to reduce their overall risk, and this
should be part of the therapeutic plan. Certainly in those
with a high-risk ASCVD risk score (Z7.5), the ﬁrst part of the
treatment plan must be addressing lifestyle and ASCVD risk
factors before initiation of any statin therapy. In addition, the
guidelines recommend that a discussion of the potential for
beneﬁt vs the potential for adverse effects of statin be part of
the management. It should include an informed patient
preference so that she can decide whether or not a statin
should be given. In the Look AHEAD trial, men and women
with diabetes had improvements in all ASCVD risk factors
with intensive lifestyle change, aside from LDL lowering [41].
Despite these improvements, there was no improvement in
CVD. This was despite achievement of beneﬁcial lifestyle
change that is likely not to be improved upon in clinical
practice. Still, the guidelines placed strong emphasis on
improved lifestyle. The lifestyle guidelines and the obesity
guidelines that were presented and published simultaneouslywith the cholesterol guidelines focus on how lifestyle changes
can improve ASCVD risk factors and help in weight manage-
ment [42,43]. The risk assessment guideline has offered a
lifetime risk estimator that is crucial for women to under-
stand their long-term risk and to motivate lifestyle changes to
improve ASCVD risk, particularly when their short-term risk
is low yet lifetime risk is high [7]. This was expressly to be
used in those 20–59 years old to enhance the discussion for
improvement in risk factors through more optimal lifestyle.
The cholesterol guidelines have made lifestyle an integral
part of the risk discussion. Moreover, the follow-up of lipid
values on ﬁxed statin doses still requires periodic LDL-C to
determine both adequacy and adherence to therapy. Lifestyle
can help address weight gain that can occur with statin
therapy presumably because lifestyle is not emphasized.Conclusions
The new cholesterol guidelines have no sex-speciﬁc differ-
ences in recommendations and emphasize risk factor and
lifestyle optimization as the initial therapy for all women.
They emphasize an appropriate intensity of proven, ﬁxed-
dose statin therapy to lower ASCVD risk for both men and
women (Table 3). These guidelines no longer recommend a
LDL-C target-driven approach or drug treatment of HDL-C or
non-HDL-C. The associated lifestyle and obesity guidelines do
indicate that non-HDL-C especially may improve with more
optimal lifestyle but there are no arbitrary targets. The
guidelines are evidence-based from randomized control trials
that have clearly demonstrated improved outcomes using
statin therapy in those with ASCVD and those at high risk of
ASCVD, not based on LDL targets but rather LDL lowering.
They are an evidence-based approach to treating women for
both primary prevention and secondary prevention.
Reliance on meta-analysis ﬁndings has its own limitations,
and certainly cannot replace appropriately powered random-
ized controlled trials. A meta-analysis is a retrospective study
that is subject to the limitations of the studies that were
included. In addition, studies in a meta-analysis cannot
always be easily compared as a group even with heteroge-
neity analysis, given the variance in the different studies, the
different statins and doses used, the differences in the
populations studied in individual studies, and the duration
of follow-up. Certainly, studies that are not included in a
meta-analysis (often not included if the investigators cannot
get the data needed for analysis) can bias the results of this
method of analysis. Over-reliance on a meta-analysis to
“answer” the question regarding statins in primary preven-
tion in women disserves this now majority CVD group. A
randomized controlled trial in an adequate at-risk population
of women for a long enough duration is needed.
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